GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of "Reduce" by Brokerages

Key Points

• GSK PLC Sponsored ADR has an average consensus rating of "Reduce" from seven brokerages, with one analyst recommending a sell and six recommending a hold.
• The company's recent earnings report exceeded analyst expectations, with a reported $1.23 EPS on revenue of $10.64 billion, up 1.3% from the same quarter last year.
• GSK also declared a quarterly dividend of $0.4206, leading to an annualized payout of $1.68 and a yield of 4.1%.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) has received an average rating of "Reduce" from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $37.3750.

Several research firms have issued reports on GSK. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd.

Institutional Trading of GSK

A number of institutional investors and hedge funds have recently made changes to their positions in GSK. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of GSK in the second quarter valued at approximately $25,000. HHM Wealth Advisors LLC lifted its stake in GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC purchased a new stake in shares of GSK in the 1st quarter valued at $31,000. SOA Wealth Advisors LLC. lifted its stake in GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company's stock worth $32,000 after acquiring an additional 605 shares in the last quarter. Finally, Richardson Financial Services Inc. lifted its stake in GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of GSK stock opened at $40.81 on Friday. The stock's fifty day moving average price is $38.74 and its 200-day moving average price is $38.47. GSK has a 12 month low of $31.72 and a 12 month high of $43.62. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The firm has a market cap of $83.12 billion, a P/E ratio of 18.89, a P/E/G ratio of 2.07 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. During the same quarter in the previous year, the firm earned $0.43 earnings per share. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities research analysts expect that GSK will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.1%. GSK's payout ratio is presently 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.